RecruitingNot Applicable

Effectiveness and Implementation of a Community-based Health Coach-led Artificial Intelligence (AI)-Powered Digital Self-Regulation Program for Individuals With Metabolic Syndrome (MetS)

Singapore316 participantsStarted 2026-01-01

Plain-language summary

This study aims to evaluate the effectiveness of the Lifestyle Intervention for Gentle, Healthy Transformation and Enhanced Weight Reduction-metabolic syndrome (LIGHTER-MetS) program on dietary self-regulation and cardiovascular risk among individuals with metabolic syndrome (MetS). The LIGHTER-MetS program, a community-based, grassroots-led initiative, integrates health coaching with the eTRIP© app to promote sustainable lifestyle changes focusing on diet, exercise, and emotion regulation.

Who can participate

Age range21 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. are between 21 to 65 years of age;
✓. have a waist circumference ≥90 cm in men and ≥80 cm in women;
✓. have 2 or more of the following to be classified as having metabolic syndrome:
✓. are not receiving other structured lifestyle modification programs;
✓. consent to audio-recording;
✓. English speaking and literate.

Exclusion criteria

✕. underwent or are scheduled for metabolic surgery within 1 year;
✕. are pregnant or planning for pregnancy at the time of recruitment;
✕. are unable to speak English;
✕. do not own a smartphone; and
✕. are unable to provide informed consent.

What they're measuring

Self regulation of Eating Behaviour Questionnaire (SREBQ)

Timeframe: At baseline, 3, 6, and 12 months.

Cardiovascular Risk

Timeframe: At baseline, 3, 6, and 12 months.

Trial details

NCT IDNCT07410325

SponsorNational University Health System, Singapore

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-01

Contact for this trial

Jocelyn Chew

+6565168687 dbi-lab@nus.edu.sg

View on ClinicalTrials.gov More Metabolic Syndrome (MetS) trials